IRI Separation Technologies Inc.

IRI Separation Technologies Inc.

June 19, 2008 09:00 ET

IRI Separation Technologies Inc.: Corporate Update

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 19, 2008) - IRI Separation Technologies Inc. (the "Company") (TSX VENTURE:IRI) The Company is pleased to announce that it has evolved from being solely a Research and Development Company to a manufacturer and marketer of finished products. These products are marketed under the Company's registered trademark MUNO®. The Company has perfected its' antibody extraction technology and currently produces a cocktail of antibodies targeted at boosting the immune system. The Company will continue with the development of specific antibodies that will be targeted for the treatment of specific bacteria and viruses.

The Company has appointed McNeil Enterprises as its' sales agents, and McNeil has entered into a sub-agreement with Cyba Stevens. Through this arrangement, the Company's product lines are in the process of being listed in over 4000 stores across Canada. Cyba Stevens is the largest retail sales organization in Canada detailing and merchandising. For more information visit

The Company has prepared TV commercials and other advertising material in connection with a planned Canada wide launch of the Muno® Product Line scheduled for September, 2008. An initial advertising program will be launched in Western Canada in July, 2008.

The Company has, until recently, operated two manufacturing plants in Airdrie, Alberta, being; a) an Immunoglobulin extraction and purification facility; and b) an Egg Breaking facility producing liquid whole egg, yolk, and albumen. As the Company's core business is not in the liquid egg retail market, the egg breaking facility was closed as of Friday, June 13th.

The Company has retained Wellington West Capital Inc. as its agent for a potential financing, details of which shall be disclosed at a later date.

IRI Separation Technologies Inc. (TSX VENTURE:IRI) is a biotechnology company that specializes in the extraction, development and commercialization of polyclonal antibodies for virus and bacteria related health issues. Intended for use as a nutraceutical for human consumption, the antibodies are derived from chicken eggs. The antibodies are intended for both the general and specific antibody market.

Forward Looking Statements: The above contains forward looking statements that are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in our forward looking statements. Factors that could cause such differences include: changes in world markets for nutraceuticals, equity market conditions, costs and supply of materials relevant to the nutraceutical industry, change in government and changes to regulations affecting the nutraceutical industry. Forward-looking statements in this release include statements regarding future store listings, operation plans, the MUNO® product launch, and the potential financing. Although we believe the expectations reflected in our forward looking statements are reasonable, results may vary, and we cannot guarantee future results, levels of activity, performance or achievements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • IRI Separation Technologies Inc. - Investor Inquiries
    John Mason
    Chairman of the Board
    IRI Separation Technologies Inc. - Investor Relations
    Paul Frigstad
    Manager of Investor Relations
    (604) 929-7332
    1-888-822-9231 (FAX)
    IRI Separation Technologies Inc.
    Rick Stiksma
    President & CEO
    (604) 637-3152 local 522
    (604) 854-6599 (FAX)